A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects

Inclusion Criteria: * Subject voluntarily agrees to participate in this study; signs an IRB-approved informed consent * Subject is healthy as determined by the screening medical evaluation (including but not limited to medical history, physical examination and clinical laboratory evaluations) * Subject is Caucasian * Female subject must be of non-childbearing potential or post-menopausal * Male subject must agree to use a condom with spermicide and refrain from sperm donation from Day -1 until 30 days post last dose or have a vasectomy at least 6 months prior to screening * Subject is a non-smoker * Subject has a body weight \> 45 kg and BMI between 18 and 32 kg/m2 * Subject has no clinically significant vital signs finding at screening or Day -1, per the investigator's judgment * Subject has no clinically significant abnormal findings in 12-lead ECG , per the investigator's judgment, at screening Exclusion Criteria: * Subject has clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s) * Subject has abnormal 12-lead ECG at screening per protocol * Subject has any disorder that would interfere with the absorption, distribution, metabolism or excretion of drugs * Subject has any concurrent disease or condition that, in the opinion of the investigator, would make the subject unsuitable for participation in the clinical study * Subject is a current alcohol abuser and/or has a history of illicit drug abuse within 1 year prior to dosing * Subject has a positive screening test for Hepatitis B surface antigen, Hepatitis C antibody, or human immunodeficiency virus (HIV) antibody * Subject is unwilling to refrain from consumption of coffee and caffeine-containing foods and beverages from Day -1 until discharge on Day 14 * Subject is unwilling to abstain from using alcohol beverages from Day -1 until discharge on Day 14 * Subject has donated blood (\> 500 mL) or blood products within 56 days prior to Day -1 * Subject has used over-the-counter (OTC) medications (including vitamins) from Day -7, or prescription medications, or herbal remedies from Day -14 until end-of-study follow-up call. By exception, acetaminophen ≤ 1000 mg/day is permitted except within 48 hours prior to Day -1 and hormone replacement therapy (HRT) is allowed throughout the study * Subject has used an investigational drug within 30 days prior to Day 1 dosing * Subject has a history of bleeding disorders